Pituitary Neuroendocrine Tumor

2

Review clinical trials related to Pituitary Neuroendocrine Tumor. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?

Participants needed: 608
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Cheng senUpdated: Sep 9, 2026Locations: 1Duration: 2 Years
Eligibility criteria

Preoperative enhanced head MRI showing a suspected diagnosis of a sella region l... [+4]

Patients with recurrent sella region tumors. [+3]

Status: Recruiting

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms

Participants needed: 882
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: Beijing Tiantan HospitalUpdated: Jan 14, 2025Locations: 1
Eligibility criteria

(1) Age range: 18-70 years old; [+4]

(1) Patients with a history of Cushing's disease or adrenal insufficiency; [+3]